Medical use of pentacyclic triterpenoid saponin and pharmaceutical composition thereof

A technology of pentacyclic triterpene saponins and compositions, which is applied in the field of medicine and can solve problems such as unclear prevention and treatment effects

Inactive Publication Date: 2019-09-06
CHINA PHARM UNIV
View PDF6 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the preventive and therapeutic effects of the above-mentioned pe

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medical use of pentacyclic triterpenoid saponin and pharmaceutical composition thereof
  • Medical use of pentacyclic triterpenoid saponin and pharmaceutical composition thereof
  • Medical use of pentacyclic triterpenoid saponin and pharmaceutical composition thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0065] Agonist activity of pentacyclic triterpene saponins on AMPK in Huh-7 cells

[0066] The agonistic activity of compounds on AMPK in Huh-7 cells was detected by Western Blot method.

[0067] Cell culture conditions: Huh-7 cells: DMEM complete medium (containing 10% fetal bovine serum and 1% streptomycin / penicillin) in 5% CO 2 cultured in a 37°C incubator.

[0068]Antibodies: anti-AMPK (CST, 2532S); anti-pAMPK (CST, 2535S).

[0069] Western Blot experiment: To detect the effect of the compound on the phosphorylation level of AMPK in Huh-7 cells: cells with a proportion of living cells above 90% were used for the experiment. In 12-well plates, Huh-7 cells were plated at 250,000 per well, placed in 5% CO 2 After 12 hours, the original medium was discarded, and the complete medium containing pentacyclic triterpenoid saponins was added. The final concentration of the tested pentacyclic triterpene saponins was set to 10 μM, and the administration time was 12 hours. AICAR (...

Embodiment 2

[0075] Effects of pentacyclic triterpene saponins on the downstream signaling pathway of AMPK in Huh-7 cells

[0076] Western Blot method was used to detect the effect of compounds on the downstream signaling pathway of AMPK in Huh-7 cells.

[0077] Cell culture conditions: Huh-7 cells: DMEM complete medium (containing 10% fetal bovine serum and 1% streptomycin / penicillin) in 5% CO 2 cultured in a 37°C incubator.

[0078] Antibodies: anti-ACC(CST,3676S); anti-pACC(CST,11818S); anti-mTOR(CST,2983S); anti-pmTOR(CST,5536S); anti-PGC1α(Abcam,ab54481); (Abcam, ab76228).

[0079] Western Blot experiment: detecting the effect of the compound on the downstream signaling pathway of AMPK in Huh-7 cells:

[0080] Cells with a live cell ratio above 90% were used for experiments. In 12-well plates, Huh-7 cells were plated at 250,000 per well, placed in 5% CO 2 After 12 hours, the original medium was discarded, and the complete medium containing pentacyclic triterpenoid saponins was ad...

Embodiment 3

[0083] Protective effect of ginsenoside Ro (compound of formula (I)) on high-fat diet (HFD)-induced NASH rat model.

[0084] Animals: 32 male SD rats, SPF grade, 6 weeks old, weighing 220 g, purchased from Beijing Weitong Lihua. All animals were maintained on a 12-h alternating circadian rhythm with free access to food and drink.

[0085] Instruments: animal weight scales; slicers; automatic biochemical analyzers; inverted microscopes

[0086] Reagents: Ginsenoside Ro(I) was purchased from Shanghai Boka Chemical Technology Co., Ltd.; obeticholic acid (OCA) was purchased from Jiangsu Vicare Pharmaceutical Technology Co., Ltd.; high-fat feed was purchased from Research Diets (D12492, 60kcal%); Standard feed was purchased from Research Diets (D12450B, 10 kcal%).

[0087] experiment procedure:

[0088] 1. Animal grouping and modeling

[0089] Rats were randomly divided into 4 groups according to body weight: control group (CHOW), high-fat diet model group (HFD), positive drug ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses an application of pentacyclic triterpenoid saponin represented by formulas (I) to (XIII) for the preparation of a medicine for preventing or treating AMPK-mediated diseases including fatty liver disease, inflammatory bowel disease, respiratory disease, diabetic complications and polycystic kidney disease. The compounds of formula (I) to (XIII) are especially usefulfor nonalcoholic simple fatty liver, nonalcoholic steatohepatitis, non-alcoholic steatohepatitis-induced cirrhosis, ulcerative colitis, Crohn's disease, chronic obstructive Pulmonary diseases, asthma,idiopathic pulmonary fibrosis, cystic fibrosis, allergic rhinitis, diabetic nephropathy, diabetic cardiomyopathy, diabetic ulcers, and autosomal dominant polycystic kidney disease. A pharmaceutical composition for preventing and treating the AMPK-mediated diseases of the present invention comprises a therapeutically effective amount of the compounds of the formula (I) to (XIII) or a pharmaceutically acceptable salt or a solvate thereof as an active ingredient and a pharmaceutically acceptable excipient.

Description

technical field [0001] The present invention belongs to the field of medicine, and specifically relates to the use of pentacyclic triterpene saponins in the preparation of medicines for preventing or treating AMPK-mediated diseases and a pharmaceutical composition. The pharmaceutical composition is very effective for AMPK-mediated diseases, comprising Pentacyclic triterpene saponins or pharmaceutically acceptable salts or solvates thereof are used as active ingredients. The AMPK-mediated diseases include fatty liver disease, inflammatory bowel disease, respiratory system disease, diabetes complications and polycystic kidney disease, etc., especially non-alcoholic simple fatty liver, non-alcoholic steatohepatitis, non-alcoholic fatty Hepatitis-induced cirrhosis, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, asthma, idiopathic pulmonary fibrosis, cystic fibrosis, allergic rhinitis, diabetic nephropathy, diabetic cardiomyopathy, diabetic ulcer and a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/704A61K31/7048A61K31/7024A61P1/16A61P1/00A61P29/00A61P11/00A61P3/10A61P13/12A61P1/04A61P11/06A61P11/02A61P37/08A61P9/00A61P3/00A61P3/06A61P3/04A61P9/10A61P9/12A61P9/04A61P9/06A61P27/02A61P25/00A61P19/06A61P19/10A61P5/50A61P19/02A61P19/08A61P35/00A61P35/02A61P17/06A61P17/00A61P25/16A61P25/28A61P25/24A61P25/14A61P21/00
CPCA61K31/704A61K31/7048A61K31/7024A61P1/16A61P1/00A61P29/00A61P11/00A61P3/10A61P13/12A61P1/04A61P11/06A61P11/02A61P37/08A61P9/00A61P3/00A61P3/06A61P3/04A61P9/10A61P9/12A61P9/04A61P9/06A61P27/02A61P25/00A61P19/06A61P19/10A61P5/50A61P19/02A61P19/08A61P35/00A61P35/02A61P17/06A61P17/00A61P25/16A61P25/28A61P25/24A61P25/14A61P21/00A61K31/7034
Inventor 孙宏斌刘柳戴量柳军
Owner CHINA PHARM UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap